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Carcinogenic Effects of Chronic
Exposure to Very Low Levels of
Toxic Substances
by Richard Peto*
Dogma
The sort of situation that I wish to consider is
contamination of the air around vinyl chloride
plants with low levels of vinyl chloride monomer.
People living nearby would be exposed to it con-
tinuously for however many decades they lived
there. If some cancers are caused by ambient levels
of (say) 0.01 ppm, I want to discuss the likely ef-
fects on the numbers of cancers and the age dis-
tribution of these cancers that would result from a
different ambient concentration-0.00I ppm, or 0.1
ppm, for example. I believe that what should in
general be expected in such circumstances is that
the age distribution of the cancers that are caused
will be the same whatever the dose rate may be;
lower dose rates will simply cause fewer cancers
than higher dose rates would do, but the age dis-
tribution will be almost identical. Moreover, the
actual number of extra cancers will, when the dose
rate is sufficiently low, simply be proportional to
the dose rate: if the dose rate is low, halving it will
halve the numbers of cancers, quartering it willjust
quarter the number of cancers, and so on; no
"threshold" should be anticipated.
I would, of course, expect to find the same sort of
results in other circumstances where humans are
exposed to chronic low doses ofother toxic agents,
and I would also expect to find this in animal ex-
periments involving chronic exposure of animals to
low dosage rates.
*Department ofthe Regius, Professor of Medicine, Radcliffe In-
firmary, Oxford OX2 6HE, England.
Rationalization of
Dogmatic Beliefs
Let us consider, for agiven level ofchronic expo-
sure to a certain agent at an average dose rate of d
units per day, a graph (Fig. 1) ofP (a, d), the proba-
bility that a person exposed for life will get the
cancer of interest at age a years, if he does not die
before that age. [We have to include the proviso
about not dying previously; P(a, d) as defined is
determined by cancer induction processes, but the
absolute chance of cancer at age a, which equals
P(a, d) multiplied by the probability of still being
alive at age a, would depend on all sorts of other
things-road traffic accidents, homicide, heart dis-
ease, and so on-which are irrelevant to the biology
of cancer induction.]
To help cause cancer, an agent must help alter a
target cell in such a way that this alteration, to-
gether with other alterations which the cell suffers
(previously or subsequently), transforms the cell's
phenotype from normal to neoplastic. Whatever the
nature ofthis alteration, there must be other ways in
which it (or an alteration equivalent to it) could have
been effected; mammalian biochemistry is so com-
plex that almost any biochemical state could be
reached by several different routes, and moreover
other carcinogens which act similarly to the test
carcinogen are likely to be present in trace amounts.
Let the total effective dose of agents causing this
particular cellularchange be called D, where D = do
+ d; do is due to background carcinogens, spon-
taneous cellular accidents and so on, while d, as
before, is the dose rate ofthe toxic substance we are
concerned with. For example, if the carcinogen of
interest acts by being a mutagen, do might be a mea-
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FIGURE 1. Hypothetical dose/response relationship, giving
cancer incidence at a particular age against daily exposure
rate to a particular carcinogen. The exact shape ofthe graph
as the dose-rate increases does not matter much; it couldjust
as well be a straight line or a line curving in a completely
different way, and the later arguments about low doses would
still hold. The only important points to note are that there is
still some risk even at zero dose, and that the line does not
become horizontal as zero dose is approached.
P(a,d)
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FIGURE 2. The same hypothetical dose/response relationship as
in Figure 1, but now with the age-specific risk plotted against
the total effective dose D, which includes not only the applied
dose d ofthe test carcinogen but also a quantity representing
background processes, either other carcinogens or spontane-
ous cellularaccidents, which can produce biochemical effects
which are functionally equivalent to those by which the test
agent causes cancer. (That portion ofthis graph below d = 0
cannot, ofcourse, be observed simply by varying the applied
dose of the test carcinogen, unless the background can also
be reduced.)
sure ofthe frequency ofequivalent mutations which
occur either spontaneously or because of other
agents contaminating the environment.
Now consider a graph ofP (a, d) against D (Fig.
2). The point D = do (corresponding to d = 0) on
this graph is offboth the axes, and so as the graph of
P against D crosses the line D = do it will in general
have positive slope. Positive slope at d = 0 is suffi-
cient (see Appendix) to establish my dogma; (1) that
at low dose rates, the age distribution of extra
tumors is independent of the dose rate and (2) that,
at low dose rates, the expected number of extra
tumors is simply proportional to the dose rate.
Qualifications
Some substances exert their carcinogenic effect
by producing a pathological change (e.g., formation
of a fibrous capsule, formation of bladder calculi,
destruction of sperm ducts, suppression of ovula-
tion, or something), such that this macroscopic
change then predisposes to cancer. For some such
processes "threshold dose rates," below which the
change will definitely not occur, might exist. How-
ever, it should be remembered, for a hypothetical
agent which is carcinogenic because it suppresses
ovulation, that although, for example, I ug of daily
estrogen would not suppress ovulation in most
females, I ,ug of daily estrogen to everyone in the
population might make the women who are already
almost completely anovulatory completely so, and
might make those with irregular ovulation ovulate a
little less frequently. Thus, because of the wild,
outbred heterogeneity of humanity, even agents
with threshold-type action in most individuals will
sometimes comply with these dogma.
There may thus be a few exceptions, but the ar-
guments are very general and difficult to circum-
vent, so regulatory agencies should, in any particu-
lar case, expect these dogma to apply unless there is
specific evidence to the contrary. (It is difficult to
imagine what evidence could contradict these
dogma for the wide class of substances which are
carcinogenic by virtue oftheir mutagenicity.) These
dogma should, therefore, be a foundation of reg-
ulatory action.
Counter Arguments
Two points are often made by people who do not
agree with these arguments. One is intuitive; in-
stead of discussing whether thresholds exist, this
question is bypassed and instead the question of
where the thresholds exist is discussed. The ob-
servable dose range (of, say, 1020 or 1025 molecules),
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range so low that it is, in common parlance,
"safe" 100 or 102 molecules, for example. (Actu-
ally, the risk from 102 molecules might in fact be
about 10-18 times the risk from 1020 molecules-that
is certainly "safe," although it is not zero.) The
argument then proceeds to ask where, between 100
and 1020 molecules, safety ceases. To expound this
argument is to expose it, especially if we add 1020
molecules of other (background) carcinogens to
each numbercited; the argumentdepends wholly on
verbal confusion between a "safe" risk and a zero
risk.
The second counterargument is more interesting.
Both Blum and Druckrey have observed that when
various (high) dose levels of a carcinogenic agent
are given repeatedly to laboratory animals, the time
T50 until half the animals have cancer is approxi-
mately proportional to d1'3. This has led to the hope,
which I believe to be misguided, that at low enough
dose levels almost all tumors would occurlong after
age 100 and so would be irrelevant to the human
condition. (In addition, Blum observed that the
variance of the logarithms of the times at which
tumors arose was independent of dose; only the
mean of the logarithms of the tumor times changed
as the dose rate varied.)
The point is that the doses given in these experi-
ments were so high that, had we been able to excise
each tumor as it arose, each animal would in ex-
pectation have developed several tumors during its
natural lifespan. Ifan animal would have developed
several tumors, each with a similar age distribution,
then what Blum or Druckrey would observe would
only be the first of these several tumors. As with
decreasing dose, fewer tumors per animal arise, so
the expected time of the first of the tumors on this
animal will increase. However, this increase will
not continue indefinitely; ifthe expected number of
tumors per animal is only 0.1, for example, then so
few animals would get two or more tumors that the
effects ofthe first tumor obscuring later tumors will
be negligible, and at all total incidence levels below
10% there will be no further such effect of
dose level on the age distribution of those tumors
which are observed. It is noteworthy that if Ar-
mitage and Doll's multistage model of cancer is
accepted, leading to an incidence rate of can-
cer among cancer-free survivors which is propor-
tional to (d + do)n (age)k, then Blum and Druckrey's
quantitative results-median proportional to (d +
do)(nl+kl, and constant variance of the logarithm of
tumor induction time-would be predicted, as
would my dogma. (This doesn't prove my dogma,
but it does prove the Blum and Druckrey's experi-
mental results are consistent with them.) These ar-
guments, with references, are developed more fully
in a recent review on multistage models (1).
I shall now outline the extent to which experi-
mental results can be used to characterize the dose
levels at which linearity begins to obtain, and the
risks that then exist.
Uses of Experimental Results to
Infer Dose-Response Relation-
ships for Low Doses
Because of statistical uncertainties in the differ-
ences between the numbers of tumors found in a
control group ofanimals and a treated group ofani-
mals, cancer risks lower than about 10% cannot be
accurately characterized, even by large experi-
ments. The experimentally observable range of at-
tributable risk is therefore the range 10% and up-
wards, and the dosage necessary to give an attribut-
able risk of 1% cannot be determined by direct ex-
periment-likewise, norcan the effects ofstill lower
doses be characterized by direct experiment.
Because of this, much work has gone into the
fitting of mathematical models: at this conference,
Brown and Crump and Guess have presented their
work on this problem, and Hartley would have done
so had he been able to attend. These models all
attempt to use experimental data (in the risk range
10% and upwards) to estimate the dose-response
relationship in the unobservable range (1% and
downwards). It seems to me that these authors have
all reached qualitatively similar conclusions, and
that although the detail of their results in any par-
ticular case will depend on the details ofthe models
they happen to fit (none of which models, we must
remember, will precisely fit reality), the qualitative
conclusions they reach would have been reached
whatever class of models they had fitted, and that
these qualitative conclusions are therefore valid as a
basis for legislation.
The statistical method is to consider a class of
"possible" graphs of risk against dose, and then to
suppose that the true graph of risk against applied
dose plus background dose is one of these possi-
bles. Selection ofa particular graph and a particular
background dose leads to a specific prediction of
the risk at each dose level. Among the range of
selections (of graph and background) which fit the
observed data as well, ornearly as well, as possible,
what will the range of predicted risks at very low
doses be? Rather curiously, the range of possible
risks at low doses does notdepend very strongly on
the class ofgraphs we choose to consider as "pos-
sible" graphs ofrisk against dose. Three main types
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quences of these statistical methods for each type
of data are outlined below.
Particular Case No. 1
The dose-response relationship in the observable
range is found to be roughly a straight line (as, for
example, with cigarette smoke and lung cancer in
man). Here the graph of attributable risk against
dose rate will go straight through zero, with a slope
approximately equal to the slope seen in the ob-
servable range and confidence limits approximately
equal to the confidence limits on a straight line
through zero and the observed data points. The
upper and lower confidence limits on the risk at low
doses will thus usually differfrom each otherby less
than a factor of 2, and the risk at low doses is
therefore known sufficiently accurately to assist in
rational legislation.
Particular Case No. 2
We find no significant effect at any of the dose
levels: the substance is, as far as we know, not a
carcinogen. In this case the lower confidence limit
is obviously zero, and (to within a factor ofabout 2)
the upper confidence limit is a straight line through
zero with slope such that at the highest experimen-
tal dose the risk roughly equals one or two S.E.'s of
the difference in risk between the highest dose
group and the control group. (This will be true even
if the observed risk in the high-dose group happens
to be lower than the observed risk in the controls:
the maximum likelihood estimate of attributable
risk due to the high dose is then zero, and the
quoted rule follows from staying within an appro-
priate distance of the maximum.) This gives us a
triangular confidence region which will usually be
no use to legislators, thus expressing mathemati-
cally the common-sense idea that animal experi-
ments cannot demonstrate noncarcinogenicity,
even for animals.
Particular Case No. 3
We find such striking upward curvature of the
dose-response relationship in the observable range
as to suggest to an optimist either that a threshold
exists, or that the risk at (say) 0.1 or 0.01 of the
lowest dose which has a statistically significant ef-
fect may be very much less than 0.1 or 0.01 times
the effect at that dose level.
Unfortunately, in this case the models all concur
that the relationship could become approximately
linear just below the experimentally observable
dose range.
(Intuitively, this may be thought of as being due
to uncertainty in the effective "background" dose;
usually, several particular background doses can be
selected such that, with a suitable selection of one
of the possible graphs, the data are adequately fit-
ted. Taking the largest ofthese possible background
doses and its associated graph, the possible linearity
of the graph of "'extra risk" versus 'actual dose'
follows.) Because ofthis, the upperconfidence limit
for attributable risk is roughly a straight linejoining
the attributable risk at the lowest statistically sig-
nificant dose to zero risk at zero dose. In general,
the lower confidence limit may be some orders of
magnitude below this, and near-total uncertainty
will result. However, for a particular reasonable
class of models, Crump (2, 3) proved if the excess
risk ofa particular type ofcancer at the lowest dose
which produces a statistically significant excess of
such cancers is of the same order of magnitude as
the risk in the controls, then the lower confidence
limit does not differ widely from the (approximately
linear) upper confidence limit, and again we have
adequate accuracy to assist in rational legislation.
An example of Crump's theorem might be if the
net risk of cancer was 10-5 times the square of the
total effective dose of PAH (pg/day), and the total
effective background dose was 10 pg/day of PAH.
An applied dose ofPAH of4 pg/day would increase
the total dose to 14 pg/day, approximately doubling
the background. In the range 0-4 pg/day of applied
dose, we would have the extra risk shown in Ta-
ble 1, and this is sufficiently similar to simple pro-
portionality for legislative purposes.
Table 1.
Applied dose
of PAH, pg/day Extra risk per 105
4 96
3 69
2 44
1 21
x, where x <1 20x < risk < 21 x
0 0
Appendix
If at each particular age the graph of P(a, d)
against d has positive slope at d = 0, then at low
dose rates itfollows, first, thatthe expected number
of extra cancers is simply proportional to the dose
rate and, second, that the age distribution of these
extra cancers is independent of the dose rate.
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d = 0 be written x(a). In a population of N indi-
viduals exposed to the chronic dose level d, the
probability of attaining age a is x(a) exp {- fP(a,
d) da}, which equalsx(a) [1 - fP(a,d) da + o(d)],
the last term in which denotes a quantity which be-
comes relatively negligible for small enough d. (In
other words, as d becomes small, the age distribu-
tion comes to be determined by diseases other than
cancer induced by the substance of interest.) The
expected number of cancers induced at age a is
therefore
N P(a, d) [x(a)] [l-fP(a, d) da + o(d)]
Writing ka = N x(a) (PIdd)d = 09 ka > o and this
expected number reduces to ka d + o(d2), which is
adequately approximated bykad for small enoughd.
The actual number of extra cancers at each age is
thus proportional to d, and the required results fol-
low; for example, doubling d will simply double the
number of extra cancers at each age, thereby
doubling the total number of extra cancers but
leaving the age distribution of the induced cancers
unaltered, etc.
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